Myrexis (Myrexis) 5-Year EBITDA Growth Rate

: 0.00% (As of Jun. 2013)

View and export this data going back to 2013. Start your Free Trial

Myrexis's EBITDA per Share for the three months ended in Jun. 2013 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison

For the Shell Companies subindustry, Myrexis's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myrexis 5-Year EBITDA Growth Rate Distribution

For the Diversified Financial Services industry and Financial Services sector, Myrexis's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Myrexis's 5-Year EBITDA Growth Rate falls into.

Myrexis 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Myrexis (OTCPK:MYRX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Myrexis 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Myrexis's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Myrexis (Myrexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020

Website

http://www.myrexis.com

Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Executives

Xstelos Corp.	10 percent owner	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe	director	1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper	director	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman	director, officer: Chairman, President and CEO	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska	director, officer: Chief Operating Officer	749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer	director, officer: President and CEO	C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden	director, officer: President and CEO	320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie	officer: Chief Operating Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines

From GuruFocus

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-09-2011

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-17-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 09-13-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-16-2010